ADMA Biologics, Inc. ADMA

$ADMA Last quarter ADMA reported $17.83 million in revenue, a 129% increase year over year. The FDA approvals are coming ahead of schedule. All the seeds that the company has planted are only beginning to bloom. Patient Stockholders will be rewarded handsomely very soon.

$ADMA Adam Grossman will be presenting today at the Morgan Stanley 19th Annual Global Healthcare Conference at 12:30pm. This is the link for the webcast.
https://www.admabiologics.com/investors/events-and-webcasts/detail/3178/morgan-stanley-19th-annual-global-healthcare-conference

$ADMA it is possible that institutional investors are unloading more shares. If it goes under a dollar I’ll buy more. The fundamentals of this company are still good. Multiple FDA approvals and massive revenue growth.

Let us at least $5 on it ??

$ADMA If this tanks to under $1.00 tomorrow I might buy more and average down. This is so far into oversold territory it’s ridiculous.

$ADMA Grossman needs to cutback on his $2 million yearly salary as a sign of support for the investors that are watching their investment diluted. He also needs to buy more shares. Why no insider buying at these levels?

$ADMA important contacts. We need answers.

COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552| sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com

$ADMA All we can do as investors is to wait. In consideration of the stock market record high performance it difficult to be in an individual stock that keeps tanking, but ADMA is achieving its goals with many FDA approvals and skyrocketing revenue and we will be all reaping the rewards of our patience soon.

$ADMA
Perhaps the most bullish point comes from the company’s outlook and expectations. The company has a $100M revenue target exiting for this year and a goal of hitting “$300M or more with significant profitability beginning no later than the first quarter of 2024.”

In addition, the company reinforced that they are “considering alternative business opportunities to maximize stockholder value, including, for example, the acquisition or sale of specific assets or businesses, collaboration and or license agreements, or other co-development agreements or arrangements.”
https://seekingalpha.com/article/4449433-adma-biologics-feeling-bullish-after-encouraging-q2-earnings-report?_gl=1*1gyacgx*_ga*UHJqVzEwYnRrZ1FUTGxkbHVZa0dXSDdZQVFjZXRQalVJR3g2aGgtamVqRVBaWlUxaGFVZ3FKUkNRVG1XTXR6dA..

The other bullish scenario that I see is that management has been negotiating with an acquirer and canceled its ATM program in connection with such negotiations. The potential acquirer may have wanted the ATM program to be canceled so that ADMA cannot issue more dilutive offerings and essentially increase the price it would have to pay for the business. Additionally, at a certain point, if the negotiations were heating up, ADMA would have to cancel this program and would be prevented from selling shares since it would be holding material non-public information. This is certainly the most bullish scenario for why ADMA canceled its ATM program.
https://www.google.com/amp/s/seekingalpha.com/amp/article/4451135-adma-biologics-recent-significant-developments-and-their-implications-for-the-stock